A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia

BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. PATIENTS AND METHODS: We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg BID [n=4], 100 mg BID [n=5], and 200 mg BID [n=18]). We enrolled 27 pat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Lymphoma Myeloma Leuk
Главные авторы: Pemmaraju, Naveen, Kantarjian, Hagop, Kadia, Tapan, Cortes, Jorge, Borthakur, Gautam, Newberry, Kate, Garcia-Manero, Guillermo, Ravandi, Farhad, Jabbour, Elias, Dellasala, Sara, Pierce, Sherry, Verstovsek, Srdan
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4344906/
https://ncbi.nlm.nih.gov/pubmed/25441108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2014.08.003
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы